US FDA APPROVES BYDUREON® PEN (EXENATIDE EXTENDED-RELEASE FOR INJECTABLE SUSPENSION) FOR ONCE-WEEKLY TREATMENT OF ADULTS with TYPE 2 DIABETES AstraZeneca today announced that the US Food and Drug ...

AstraZeneca has received regulatory approval for a single-use pen injector to improve glycemic control in patients with type 2 diabetes – a disease with soaring prevalence rates and a huge unmet ...

AstraZeneca announced the availability of Bydureon (exenatide extended-release for injectable suspension) Pen in pharmacies across the country. Bydureon is indicated as an adjunct to diet and exercise ...

The US Food and Drug Administration (FDA) has approved extended-release exenatide in a pen form for the treatment of adults with type 2 diabetes, according to the manufacturer. AstraZeneca's exenatide ...

AstraZeneca (AZ) has finally secured US approval for a pen injector version of its once-weekly diabetes drug Bydureon after a delay of more than a year. Bydureon Pen (exenatide) had been due to reach ...

Bydureon, a glucagon-like peptide-1 (GLP-1) receptor agonist, gained approval earlier this year as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes. This ...

US regulators have given the thumbs-up to AstraZeneca's pre-filled, single-use pen injector version of its long-acting diabetes drug Bydureon. US regulators have given the thumbs-up to AstraZeneca’s ...

AstraZeneca has launched in the UK a new pre-filled pen containing its once-weekly diabetes drug Bydureon (exenatide), offering patients a simpler route of administration. AstraZeneca has launched in ...

Below are 3 natural substitutes to Bydureon that can reduce body weight and control blood sugar levels. For best results it is possible to use in a stack – this means combining 2 or more products ...

AstraZeneca has launched Bydureon as a pre-filled pen. The company will now discontinue the drug in its vial and syringe form to avoid confusion. What is Bydureon? Bydureon is the trade name of ...

WILMINGTON, Del. — AstraZeneca received approval from the Food and Drug Administration for its Bydureon pen (exenatide extended-release for injectable suspension) 2-mg, which is to be used as an ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE:AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Bydureon® Pen (exenatide extended-release for injectable ...